Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 33,144 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 2 Interventional

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

NCT01320527
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nutriceutical formulation, Placebo
Dietary Supplement · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 2 Interventional

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

NCT00444561
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
25 Years to 60 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Chula Vista, California • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Nov 4, 2026, 2:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486
View directory record Official record
Conditions
Non-small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 2 Interventional

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

NCT01594983
View directory record Official record
Conditions
Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions
LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 4, 2026, 2:45 PM EST
Completed Not applicable Interventional Results available

Alvimopan and Ileus in PSF

NCT02218190
View directory record Official record
Conditions
Ileus, Spinal Fusion
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 3 Interventional Results available

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

NCT05139810
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Nov 4, 2026, 2:45 PM EST
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

NCT07545759
View directory record Official record
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mesa, Arizona • Anaheim, California • Lancaster, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Nov 4, 2026, 2:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Turmeric and Exercise-Induced Muscle Damage and Oxinflammation

NCT04765527
View directory record Official record
Conditions
Muscular Injury
Interventions
Turmeric Strength for Joint, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of NAV-240 in Healthy Volunteers

NCT06181786
View directory record Official record
Conditions
Healthy
Interventions
NAV-240, Placebo
Drug
Lead sponsor
Navigator Medicines, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Nov 4, 2026, 2:45 PM EST
Active, not recruiting Phase 3 Interventional

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286
View directory record Official record
Conditions
HIV-1-infection
Interventions
ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 4, 2026, 2:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

NCT05246670
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Palmidrol, Placebo Administration, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Middletown, Connecticut • Urbana, Illinois • Sioux City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 3 Interventional Results available

Lurasidone Pediatric Bipolar Study

NCT02046369
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Dothan, Alabama • Culver City, California • Hartford, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

NCT03522441
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1% Gel, Placebo
Drug
Lead sponsor
Akorn, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Encino, California • Sherman Oaks, California • Brandon, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Nov 4, 2026, 2:45 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 4, 2026, 2:45 PM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

NCT06027554
View directory record Official record
Conditions
Frailty, Mild Cognitive Impairment, Aging
Interventions
Mitoquinone Mesylate, Placebo capsule
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
65 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 2 Interventional Results available

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

NCT04414618
View directory record Official record
Conditions
Coronavirus Infections
Interventions
Opaganib, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Miami, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 3 Interventional Results available

BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

NCT02819297
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, CIC
Interventions
BLI400 Laxative, BLI400 Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 3 Interventional Results available

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT02755597
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Durham, North Carolina • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125, GSK573719 62.5, GW642444 25, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 2 Interventional Results available

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

NCT00947882
View directory record Official record
Conditions
Lower Urinary Tract Symptoms (LUTS)
Interventions
Placebo, Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Homewood, Alabama • Mobile, Alabama • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT04520659
View directory record Official record
Conditions
RSV Infection
Interventions
RSV LID/ΔM2-2/1030s, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 4, 2026, 2:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

NCT06716879
View directory record Official record
Conditions
Healthy Participants
Interventions
Donzakimig, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 4, 2026, 2:45 PM EST